



Client
Patient
Physician
Billing
Specimen
Clinical Indication
Comments

Name: Last, First M _____

male female

DOB _____ SS# _____

Address _____

Patient ID _____ Facility ID _____ Other ID _____

ORDERING PHYSICIAN

Phone _____ Fax _____

Client Insurance/Patient (Please Attach Copy Insurance Info)

Insurance Company _____

Policy # _____ Group # _____

Insurance Address _____

Collection Date/Time _____ am pm

Peripheral Blood Bone Marrow Aspirate Core Biopsy

Tissue, specify site _____

Paraffin-embedded* Specimen # _____ Block # _____ Slides

*Please provide copy of Surgical Pathology Report

*Permission to exhaust block Yes No Please call to confirm

FNA, specify site _____

Fluids: BAL CSF Pleural fluid

Other specimen, specify site _____

- 204.0 ALL
- 205.0 AML
- 200.6 Anaplastic large cell lymphoma
- 174.9 Breast, unspecified
- 233.0 Carcinoma of breast
- 205.1 CML
- 238.71 Essential thrombocythemia
- 599.7 Hematuria
- 208.9 Unspecified leukemia
- 288.60 Leukocytosis, unspecified
- 238.79 Lymphoproliferative disease
- 203.0 Multiple myeloma
- 238.79 Myeloproliferative disease
- 238.75 MDS, unspecified
- 239.3 Neoplasm, unspecified breast
- 202.8 Other malignant lymphomas
- 202.7 Peripheral T-cell lymphoma
- 198.89 Secondary malignant neoplasm of other specified site

- The following support flow testing, additional diagnostic codes are required for cytogenetics/FISH:**
- 285.9 Anemia, unspecified
 - 204.1 CLL
 - 201.9 Hodgkin disease, unspecified
 - 200.7 Large cell lymphoma
 - 785.6 Lymphadenopathy
 - 185 Malignant neoplasm prostate
 - 200.4 Mantle cell lymphoma
 - 200.3 Marginal zone lymphoma
 - 273.1 Monoclonal paraproteinemia
 - 288.0 Neutropenia
 - 795.4 Nonspecific abnormal histological findings
 - 203.1 Plasma cell leukemia
 - V71.1 Suspect malignant neoplasia
 - 287.5 Thrombocytopenia, unspecified

PATHOLOGY

- BMPE** Bone Marrow Pathology Evaluation
- PBSP** Peripheral Blood Smear Evaluation
- SPP** Surgical Pathology Professional Evaluation
- SPC** Surgical Pathology Consultation

FLOW CYTOMETRY

- FLOW** Myeloid/Lymphoid Markers (leukemia/myeloma/non-Hodgkin lymphoma)
For limited/targeted markers, please check:
 - Lymphoid markers **only**
 - B cell/plasma cell markers **only** (i.e. monoclonal gammopathy)
 - Residual disease (please specify disease)
 - Other (please specify) _____
- For reflex testing if FLOW positive for B-CLL clone
 - FLOW ZAP70**
 - F CLL** (FISH)
- FLOW PNH** Paroxysmal nocturnal hemoglobinuria (CD55,CD59,FLAER)
- FLOW BAL** Bronchoalveolar lavage (CD4:CD8)
- FLOW LAD** Leukocyte adhesion (CD11a,CD11b,CD11c,CD18)
- FLOW ZAP70** ZAP-70
- FLOW CD4** T cell subsets (CD3,CD4,CD8,CD4:CD8)
- FLOW EX** Lymphocyte analysis (T cell subsets, CD19,CD56)
- PLOIDY** Cell cycle analysis; DNA Ploidy and S Phase

FISH/CYTOGENETICS

FISH Profiles

- F AALL** Adult: t(9;22), 11q23, t(12;21)
- F CLL** p53, 11q22, 13q14/13q34,+12, 6q-
- F MDS** -5/5q-, -7/7q-, +8, 20q-
- F MPD** t(9;22), +8, 13q14, 20q- **reflex JAK2** if t(9;22) neg
- F MM** +5/+9/+15, 13q14, p53, t(11;14), includes reflex **F FGFR3** t(4;14), **F IGH MAF** t(14;16) if IGH rearranged
- F PALL** Pediatric: t(9;22), +4, +10, +17, 11q23, t(12;21)

Cytogenetics

- CYTO BM** marrow
- CYTO UPB** blood
- CYTO ST** solid tumor

Common Individual FISH Probes

- F 4Q12** PDGFRA, CHIC2
- F ALK** 2p23
- F AML ETO** t(8;21)
- F API MALT** t(11;18)
- F BCL1** t(11;14)
- F BCL2** t(14;18)
- F BCL6** 3q27
- F BCR ABL** t(9;22)
 reflex to **JAK2** if negative
- F CBFB** t(16;16), inv(16)
- F CMYC** 8q24
- F EWSR1** 22q12 Ewing sarcoma
- F FGFR3** t(4;14)
- F GLI** Oligodendroglioma 1p36-/19q13-
- F HER2** Her2/neu breast cancer
- F IGH** 14q32
- F IGH MAF** t(14;16)
- F IGH MALT** t(14;18)
- F IGH MYC** t(8;14)
- F MLL** 11q23
- F N MYC** 2p24
- F P53** 17p13
- F PML RARA** t(15;17)
- F PTEN** 10q23-
- F SRY** X/Y sex-mismatch
- F URO** +3, +7, +17, 9p21- bladder cancer
- Other** _____

MOLECULAR ONCOLOGY

- ABL G** kinase Gleevec® resistance
- BRAF** V600 mutation, EGFR inhibitor/response
- FLT3** mutation analysis for ITD
- KRAS** mutation, EGFR inhibitor/response
 reflex to **BRAF** if KRAS normal
- NPM1** mutational analysis
- P AML** mutation profile (FLT3 and NPM1)
 reflex to **CEBPA** testing if FLT3 and NPM1 negative
- P BCELL** Ig heavy chain gene rearrangement
 reflex to **P IGK** kappa light chain if IGH negative
- P BCL2** t(14;18) gene rearrangement
- P JAK2** V617F Ph negative chronic MPD
- P TCR** T cell receptor gamma gene rearrangement
- UGT1A1** genotyping **Camptosar™** toxicity

Quantitative PCR and minimal residual disease testing

- P BCR ABL** initial diagnostic workup
- P BCR ABLm** disease monitoring
- P PML RARA** initial diagnostic workup
- P PML RARAm** disease monitoring

IHC TC Technical Global

- I ER** **I PR** **I HER2** **I KI67**
 reflex to F HER2 if I HER2 is 1+ 2+ 3+
- I AE1/AE3** Cytokeratin cocktail, PAN
- I MSI** Microsatellite instability - MLH1, MSH2, MSH6, PMS2
- Other** _____

Circulating Tumor Cell Detection

- CELLSEARCH** check one below
 breast colon prostate